Elevation Oncology (ELEV) Stock Forecast & Price Target
Elevation Oncology (ELEV) Analyst Ratings
Bulls say
Elevation Oncology Inc. is positioned favorably due to its innovative product candidate, EO-3021, which demonstrates promising preliminary data, including a good objective response rate (ORR) of 43% in a selectively targeted patient population with the Claudin 18.2 biomarker. Upcoming data catalysts, including additional monotherapy results and first-in-human combination therapy data, could significantly enhance investor confidence and facilitate access to further capital, strengthening the company's financial position. Additionally, the potential for EO-3021 to provide a superior treatment option in combination therapies, as evidenced by its favorable safety profile and efficacy compared to established regimens, indicates a strong strategic advantage in the competitive oncology market.
Bears say
Elevation Oncology Inc. faces significant challenges that contribute to a negative outlook for its stock, primarily stemming from its inability to effectively defend its portfolio, which raises concerns about potential market share loss for its product candidates. The company's struggles with accessing capital may hamper critical business operations, prolonging the timeline to profitability and cash flow generation. Additionally, recent unfavorable clinical trial data, particularly regarding the efficacy of EO-3021 in low-expressing Claudin 18.2 patient populations, alongside the absence of revenues and significant net losses, further exacerbate investor apprehensions about the company's financial health and future prospects.
This aggregate rating is based on analysts' research of Elevation Oncology and is not a guaranteed prediction by Public.com or investment advice.
Elevation Oncology (ELEV) Analyst Forecast & Price Prediction
Start investing in Elevation Oncology (ELEV)
Order type
Buy in
Order amount
Est. shares
0 shares